Furthermore, out of the 150 potential markers identified in this study, a few proteins Defensin (DEFA4), α-2-macroglobulin receptor-associated protein (LRPAP1), Interleukin-18-binding protein (IL18BP), Interleukin-17D (IL17D) and ER degradation-enhancing α-mannosidase-like protein 2 (EDEM2) are not currently linked specifically to breast cancer and may therefore represent completely new markers of breast cancer potentially suitable for population screening applications. This evidence concerns the gene DEFA4 and breast cancer.